Efficacy and safety of nail psoriasis targeted therapies: a systematic review. | 2023 | American Journal of Clinical Dermatology |
Anti-drug antibodies of IL-17 inhibitors for psoriasis: a systematic review. | 2023 | The Journal of dermatological treatment. |
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. | 2023 | The Cochrane database of systematic reviews. |
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. | 2022 | The Cochrane Database of Systematic Reviews |
Comparison of efficacy of anti-interleukin-17 in the treatment of psoriasis between Caucasians and Asians: a systematic review and meta-analysis. | 2022 | Frontiers in Medicine |
Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes. | 2022 | RMD Open |
Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year. | 2022 | Journal of Dermatological Treatment |
Comparative efficacy and relative ranking of biologics and oral therapies for moderate-to-severe plaque psoriasis: a network meta-analysis | 2021 | Dermatology and Therapy |
Short-term efficacy of biologic therapies in moderate-to-severe plaque psoriasis: a systematic literature review and an enhanced multinomial network meta-analysis. | 2021 | Dermatology and Therapy |
Network meta-analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method. | 2021 | Journal of the European Academy of Dermatology and Venereology |
Efficacy of a second interleukin 17 inhibitor in patients with psoriasis: a systematic review and meta-analysis. | 2021 | Journal of the American Academy of Dermatology |
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis | 2021 | The Cochrane Database of Systematic Reviews |
Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis | 2021 | Journal of Dermatology Treatment |
Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis. | 2020 | Journal of the European Academy of Dermatology and Venereology |
Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. | 2020 | Journal of Dermatological Science |
Efficacy of brodalumab for moderate to severe plaque psoriasis: a Canadian network meta-analysis. | 2020 | Journal of Cutaneous Medicine and Surgery |
Short-term efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: A systematic review and network meta-analysis of randomized controlled trials. | 2019 | Journal of Immunology Research |
Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response. | 2019 | Journal of the European Academy of Dermatology and Venereology |
Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response. | 2019 | PLoS One |
A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis. | 2018 | The Journal of Dermatological Treatment |
Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. | 2018 | Journal of the American Academy of Dermatology |
The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis. | 2018 | The Journal of Dermatological Treatment |
Brodalumab for treating moderate to severe plaque psoriasis. | 2018 | NICE |
Clinical review report: brodalumab (Siliq). | 2018 | CADTH |